Corbus Pharmaceuticals Holdings, Inc.(NASDAQ : CRBP)
CRBP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-3.38%||8.00||0.7%||$559.23m|
|GILD||Gilead Sciences, Inc.||0.36%||64.89||1.0%||$472.42m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.90%||477.04||2.7%||$431.11m|
|VRTX||Vertex Pharmaceuticals, Inc.||1.10%||215.94||1.9%||$372.06m|
|ALXN||Alexion Pharmaceuticals, Inc.||-0.18%||153.73||2.0%||$315.33m|
|EXAS||EXACT Sciences Corp.||2.45%||128.00||18.4%||$194.86m|
|NBIX||Neurocrine Biosciences, Inc.||0.19%||92.97||4.9%||$172.50m|
|CRSP||CRISPR Therapeutics AG||5.67%||120.88||0.6%||$169.35m|
|TXG||10X Genomics, Inc.||4.81%||197.36||0.0%||$149.02m|
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.